Antibody-mediated targeting of TNFR2 activates CD8 + T cells in mice and promotes antitumor immunity-Reference-Cited by-同舟云学术

Antibody-mediated targeting of TNFR2 activates CD8 + T cells in mice and promotes antitumor immunity

Published:2019-10-02 Issue:512 Volume:11 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Tam Eric M.¹^ORCID,Fulton Ross B.¹^ORCID,Sampson James F.¹^ORCID,Muda Marco¹^ORCID,Camblin Adam¹,Richards Jennifer¹,Koshkaryev Alexander¹,Tang Jian¹,Kurella Vinodh¹,Jiao Yang¹,Xu Lihui¹,Zhang Kathy¹^ORCID,Kohli Neeraj¹^ORCID,Luus Lia¹^ORCID,Hutto Elizabeth²,Kumar Sandeep¹,Lulo James¹,Paragas Violette¹^ORCID,Wong Christina¹^ORCID,Suchy James¹^ORCID,Grabow Stephanie¹,Dugast Anne-Sophie¹^ORCID,Zhang Hong¹,Depis Fabien¹,Feau Sonia¹,Jakubowski Aniela¹,Qiao Wenlian¹,Craig Galina¹^ORCID,Razlog Maja¹,Qiu James¹^ORCID,Zhou Yu³,Marks James D.³,Croft Michael⁴⁵^ORCID,Drummond Daryl C.¹^ORCID,Raue Andreas¹^ORCID

Affiliation:

1. Merrimack Pharmaceuticals, Inc., Cambridge, MA 02139, USA.

2. Histo-Scientific Research Laboratories, Mount Jackson, VA 22842, USA.

3. University of California at San Francisco, San Francisco, CA 94110, USA.

4. La Jolla Institute for Immunology, La Jolla, CA 92037, USA.

5. University of California San Diego, La Jolla, CA 92037, USA.

Abstract

Anti-TNFR2 antibodies induce costimulation of T cells, complete tumor regression, and immune memory in mice and can be combined with anti-PD1.

Funder

National Cancer Institute

Publisher

American Association for the Advancement of Science (AAAS)